Lipitor's Sales Drop After Generic Entry
Lipitor (atorvastatin), Pfizer's blockbuster statin, lost nearly all its U.S. market share within months of generic competition starting November 30, 2011. Branded sales fell 85% in the first full quarter (Q1 2012) from $1.9 billion to $288 million, then plunged further to $112 million by Q2 2012—a 94% drop year-over-year.[1][2]
Timeline of the Decline
- Pre-generic (Q3 2011): Peak U.S. sales hit $2.7 billion quarterly.
- Launch month (Nov-Dec 2011): Immediate erosion as generics captured 80% of new prescriptions.
- Q1 2012: Branded share dropped to under 15%; total atorvastatin prescriptions shifted 90% generic.
- By mid-2012: Branded Lipitor held just 5-10% of the market, with annual U.S. sales falling from $5.5 billion (2010) to under $300 million (2012).[1][3]
Global sales followed suit, dropping from $12.5 billion in 2010 to $8.4 billion in 2011 and $3.8 billion in 2012.[2]
Factors Driving the Rapid Fall
Heavy generic discounting—up to 85% cheaper—sparked quick switches. Ranbaxy launched first at a steep discount, followed by 13 others. Physicians and payers favored generics immediately, with no loyalty programs stemming the tide. Pfizer's authorized generic (via Watson) accelerated the shift but couldn't save the brand.[1][4]
How It Compared to Other Blockbusters
Lipitor's decline outpaced many: Norvasc lost 80% in year one (2007), while Plavix dropped 70% post-2012 launch. Lipitor hit sub-10% share faster due to its massive $125 billion lifetime sales and crowded generic field.[3][5]
What Happened to Pfizer's Revenue
The hit cost Pfizer $3-4 billion annually short-term, but savings on manufacturing and a $2.3 billion authorized generic deal softened it. Lipitor still generated $2 billion globally by 2015 from loyal segments.[2]
[1]: FDA Orange Book and IMS Health data via FiercePharma
[2]: Pfizer annual reports 2010-2013
[3]: DrugPatentWatch.com - Atorvastatin patent expiry
[4]: Bloomberg analysis on Ranbaxy launch
[5]: EvaluatePharma blockbuster generic erosion study